242 related articles for article (PubMed ID: 35663229)
1. miR-15a and miR-15b modulate natural killer and CD8
Pathania AS; Prathipati P; Olwenyi OA; Chava S; Smith OV; Gupta SC; Chaturvedi NK; Byrareddy SN; Coulter DW; Challagundla KB
Mol Ther Oncolytics; 2022 Jun; 25():308-329. PubMed ID: 35663229
[TBL] [Abstract][Full Text] [Related]
2. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
[TBL] [Abstract][Full Text] [Related]
3. PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma.
Song M; Huang Y; Hong Y; Liu J; Zhu J; Lu S; Wang J; Sun F; Huang J; Xu J; Tang Y; Xia JC; Zhang Y
Oncoimmunology; 2024; 13(1):2289738. PubMed ID: 38125723
[TBL] [Abstract][Full Text] [Related]
4. LncRNA KCNQ1OT1 sponges miR-15a to promote immune evasion and malignant progression of prostate cancer via up-regulating PD-L1.
Chen QH; Li B; Liu DG; Zhang B; Yang X; Tu YL
Cancer Cell Int; 2020; 20():394. PubMed ID: 32821247
[TBL] [Abstract][Full Text] [Related]
5. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
6. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
7. LncRNA MEG8 promotes NSCLC progression by modulating the miR-15a-5p-miR-15b-5p/PSAT1 axis.
Guo K; Qi D; Huang B
Cancer Cell Int; 2021 Feb; 21(1):84. PubMed ID: 33526036
[TBL] [Abstract][Full Text] [Related]
8. Identification of neuroblastoma cell lines with uncommon TAZ
Canzonetta C; Pelosi A; Di Matteo S; Veneziani I; Tumino N; Vacca P; Munari E; Pezzullo M; Theuer C; De Vito R; Pistoia V; Tomao L; Locatelli F; Moretta L; Caruana I; Azzarone B
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452207
[TBL] [Abstract][Full Text] [Related]
9. Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta.
Siebert N; Zumpe M; Schwencke CH; Biskupski S; Troschke-Meurer S; Leopold J; Zikoridse A; Lode HN
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444427
[TBL] [Abstract][Full Text] [Related]
10. Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway.
Li X; Wang S; Mu W; Barry J; Han A; Carpenter RL; Jiang BH; Peiper SC; Mahoney MG; Aplin AE; Ren H; He J
J Exp Clin Cancer Res; 2022 Jan; 41(1):41. PubMed ID: 35086548
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
12. The
Xu G; Mo L; Wu C; Shen X; Dong H; Yu L; Pan P; Pan K
Ren Fail; 2019 Nov; 41(1):955-966. PubMed ID: 31658856
[No Abstract] [Full Text] [Related]
13. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
[TBL] [Abstract][Full Text] [Related]
14. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
15. Exosomes derived from bone marrow mesenchymal stem cells inhibit human aortic vascular smooth muscle cells calcification via the miR-15a/15b/16/NFATc3/OCN axis.
Luo F; Guo W; Liu W
Biochem Biophys Res Commun; 2022 Dec; 635():65-76. PubMed ID: 36257194
[TBL] [Abstract][Full Text] [Related]
16. A scoping review on the significance of programmed death-ligand 1-inhibiting microRNAs in non-small cell lung treatment: A single-cell RNA sequencing-based study.
Shadbad MA; Ghorbaninezhad F; Hassanian H; Ahangar NK; Hosseinkhani N; Derakhshani A; Shekari N; Brunetti O; Silvestris N; Baradaran B
Front Med (Lausanne); 2022; 9():1027758. PubMed ID: 36388933
[TBL] [Abstract][Full Text] [Related]
17. Hsa_circ_0046523 Mediates an Immunosuppressive Tumor Microenvironment by Regulating MiR-148a-3p/PD-L1 Axis in Pancreatic Cancer.
Fu X; Sun G; Tu S; Fang K; Xiong Y; Tu Y; Zha M; Xiao T; Xiao W
Front Oncol; 2022; 12():877376. PubMed ID: 35712476
[TBL] [Abstract][Full Text] [Related]
18. Protective role of astragaloside IV in gastric cancer through regulation of microRNA-195-5p-mediated PD-L1.
Liu W; Chen H; Wang D
Immunopharmacol Immunotoxicol; 2021 Aug; 43(4):443-451. PubMed ID: 34124983
[TBL] [Abstract][Full Text] [Related]
19. A Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma.
Assal RA; Elemam NM; Mekky RY; Attia AA; Soliman AH; Gomaa AI; Efthimiadou EK; Braoudaki M; Fahmy SA; Youness RA
Transl Oncol; 2024 Apr; 45():101961. PubMed ID: 38631259
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
